AN2 Therapeutics公司（AN2 Therapeutics, Inc.）已与杰富瑞集团（Jefferies LLC）达成一项公开市场销售协议。该协议签署日期为2026年4月9日，相关文件已正式提交美国证券交易委员会（SEC）备案。
根据协议条款，杰富瑞集团将作为销售代理，在公开市场上代AN2 Therapeutics公司出售其普通股股份。此类融资安排通常用于上市公司灵活筹集资金，同时最大限度减少对股价的直接冲击。
此次协议的签署标志着AN2 Therapeutics公司正积极拓展融资渠道，为后续业务发展提供资金支持。生物制药企业的研发周期长、资金需求大，通过资本市场操作获取资金是其维持研发投入的重要方式。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.